New allergy vaccine could end spring sniffles
NCT ID NCT07155499
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new treatment called GNR-127 for people with seasonal allergies to birch pollen. The treatment is a protein that aims to reduce allergy symptoms like sneezing, runny nose, and itchy eyes. The trial involves 150 adults and will check for safety and how well it works compared to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GNR-127 (a recombinant birch pollen allergen protein)
What this could lead to
If it works, this could lead to a treatment that reduces or eliminates allergy symptoms like sneezing and itchy eyes during birch pollen season.
What could go wrong
This is an early first-in-human trial, so safety and effectiveness are not yet proven. The results may not lead to a widely available treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Research Center - Institute of Immunology Federal Medical-Biological Agency
Moscow, 115522, Russia